Navigation Links
InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
Date:1/4/2012

BRISBANE, Calif., Jan. 4, 2012 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that it will report unaudited fourth quarter 2011 revenue related to sales of Esbriet® (pirfenidone) in Germany, as well as other metrics related to the Esbriet launch, prior to the open of the U.S. markets on Thursday, January 5, 2012.  A live conference call and webcast will be hosted by InterMune at 8:30 a.m. Eastern time that same day.  InterMune also plans to report additional efficacy and survival data from the ongoing RECAP extension study of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF).  The company will review its plans to gain reimbursement for Esbriet across Europe and an expert in German drug reimbursement law will answer questions on the call.  Additionally, the company will update its expense guidance for 2011 and will provide forward-looking expense guidance for the full year 2012.  

Interested investors and others may participate in the conference call by dialing 888-567-5125 (U.S.) or 706-643-9223 (international), conference ID# 40200495.  To access the live webcast of the call, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

A replay of the webcast and teleconference will be available on the company's website approximately three hours after the call and will remain available until the company's next earnings call.

A telephonic replay will be available for 10 business days following the call and can be accessed by dialing 855-859-2056 (U.S.) or 404-537-3406 (international), and entering the conference ID# 40200495. 

About InterMune
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and fibrotic diseas
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. InterMune to Present at Canaccord Adams Conference
2. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
3. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
4. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
5. InterMune to Release Third Quarter 2008 Financial Results on November 6
6. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
7. InterMune to Present at Deutsche Bank Biotech Boston Confab
8. InterMune to Present at J.P. Morgan Healthcare Conference
9. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
10. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
11. InterMune Announces Issuance of U.S. Patent for ITMN-191
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2015)... ... July 24, 2015 , ... ... solution, indispensable to any modern scientific or pharmaceutical laboratory. FreezerPro® is an ... Users know precisely where a sample is located even before opening the ...
(Date:7/23/2015)... ... , ... One hundred years ago this year, 18 model airplane clubs competed ... of winning the Henry S. Villard Trophy. The Academy of Model Aeronautics has plans ... to build a Free Flight fantasy club worthy of taking home the Villard Trophy. ...
(Date:7/23/2015)... , July 23, 2015 /PRNewswire/ - Portage Biotech ... PBT.U), and Biohaven Pharmaceutical Holding Company Limited (Biohaven), ... an Investigational New Drug (IND) Application with the ... clinical testing of BHV-0223. Portage holds 54% equity ... BHV-0223 is a glutamate modulating agent and Biohaven ...
(Date:7/23/2015)... (PRWEB) , ... July 23, 2015 , ... Global ... cell research in Santiago, Chile. The symposium will feature some of the world’s ... full day of high-level scientific discussion for medical professionals in general practice. , The ...
Breaking Biology Technology:RURO, Inc. Partners with Integrated Systems Engineering to Provide Comprehensive LIMS Software to Biobanks 2RURO, Inc. Partners with Integrated Systems Engineering to Provide Comprehensive LIMS Software to Biobanks 3RURO, Inc. Partners with Integrated Systems Engineering to Provide Comprehensive LIMS Software to Biobanks 4Academy of Model Aeronautics to Start Online Fantasy Flight Competition 2Portage's Biohaven Announces IND Filing for BHV-0223 for Phase 1 Clinical Testing 2Portage's Biohaven Announces IND Filing for BHV-0223 for Phase 1 Clinical Testing 3Portage's Biohaven Announces IND Filing for BHV-0223 for Phase 1 Clinical Testing 4Global Stem Cells Group Announces Plans to Hold International Symposium on Stem Cells and Regenerative Medicine in Santiago, Chile Sept. 3-4, 2015 2Global Stem Cells Group Announces Plans to Hold International Symposium on Stem Cells and Regenerative Medicine in Santiago, Chile Sept. 3-4, 2015 3
... 2011 Oligomerix, Inc. presented results at the ... demonstrated that tau protein forms neurotoxic oligomers with ... results in tau,s self-fragmentation and in the degradation ... neurotoxic mode-of-action. Furthermore, certain tau oligomer species that ...
... RESTON, Virginia and BRNO, Czech Republic, November 16, ... Institute (MMCI) provides complete diagnostics, treatment, and ... and international patients. MMCI is the only health ... a member of the OECI (Organisation of European ...
... Livestream Info ... http://thehill.com/video/in-the-news/193083-livestreaming-genetic-testing-briefing . , Twitter: ... redefining cancer treatment, and the pace of discovery promises new ... That will be among the topics of discussion today at ...
Cached Biology Technology:A New Mechanism for Tau Protein Pathology in Alzheimer's Disease was Presented by Oligomerix, Inc. at the Society for Neuroscience Annual Meeting 2Masaryk Memorial Cancer Institute Reduces Losses and Administrative Overhead With Ekahau RTLS 2Masaryk Memorial Cancer Institute Reduces Losses and Administrative Overhead With Ekahau RTLS 3Members of Congress, Cancer Experts Address Impact of Genetic Testing on Cancer 2
(Date:7/7/2015)... July 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... growing mobile commerce market announces a revised version of one of ... commercial will air on CNBC in New York ... and San Francisco metro areas.    ... on Wocket,s ability to replace all the cards in your wallet ...
(Date:6/30/2015)... To bolster its efforts and commitment to fighting cyber fraud, ... of two new team members. Dimitri ... Raviv will act as head of strategic alliances. These ... the most secure solutions for the enterprise market. ... a provider of security and management products, which was acquired ...
(Date:6/25/2015)... , June 25, 2015 ... Market by Type (Swipe & Area), Technology, Material (Optical ... Healthcare, Commercial Security & Others) & Geography - ... marketsandmarkets, the said market is expected to reach ... 17.1%. Browse 76 market Tables ...
Breaking Biology News(10 mins):Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4
... people breathe while walking in the park, working in the ... spike their blood pressure, a new study suggests. Cardiovascular ... first to report a direct link between air pollution and ... results from these animal studies hold up, this could be ...
... time, next-generation DNA sequencing technologies have been turned on ... each year. The results will help to improve diagnosis, ... new strategies for vaccination. The study sets a ... a disease-causing bacterium: it is the first study of ...
... expectancy for patients with human immunodeficiency virus (HIV) has ... 1990s thanks to advancements in antiretroviral therapy, according to ... and Simon Fraser University in Vancouver, British Columbia. ... drop in AIDS deaths among 43,355 HIV-positive study participants ...
Cached Biology News:OSU study shows exposure to bad air raises blood pressure 2OSU study shows exposure to bad air raises blood pressure 3Defining DNA differences to track and tackle typhoid 2Defining DNA differences to track and tackle typhoid 3Anti-HIV therapy boosts life expectancy more than 13 years 2
BD BioCoat Collagen IV 150 mm Culture Dishes...
Gridded Cell Culture Petri Dish (20 mm molded in base), tissue-culture treated...
MAb to Desmoplakin I & II Desmoplakin I & II...
... PI is used in conjuction with ... in the earlier stages of apoptosis (Annexin ... are in later stages of apoptosis or ... PI is detected in the orange range ...
Biology Products: